Morning Buzz: Halliburton (HAL), Cal-Maine Foods (CALM), Exelixis, (EXEL), Yahoo (YHOO), Horizon Pharma (HZNP)

Halliburton Company (HAL) shares are up $1.01 to $41.00 in pre-market trading Monday after the company reported its second quarter earnings results.

The oilfield services firm posted earnings of $0.44 per share on revenues of $5.92 billion, down 26.5% from a year ago. Analysts were expecting EPS of $0.29 on revenues of $5.78 billion. Net income for the period ended June 30, came in at $54 million, or $0.06 per share, compared to $774 million, or $0.91 per share, a year earlier.

“We are pleased with our second quarter results, considering the headwinds facing the industry,” said in a statement Jeff Miller, President of Halliburton.

Cal-Maine Foods, Inc. (CALM) reported fourth quarter EPS of $0.95 before the opening bell Monday, compared to the consensus estimate of $1.04. Revenues increased 8.4% from last year to $403 million. Analysts expected revenues of $417.31 million. For the fiscal year 2015, the egg producer reported net income of $161.3 million, or $3.33 per diluted share, compared with net income of $109.2 million, or $2.26 per diluted share, for the same period in fiscal 2014. Revenue was reported as $1.57 billion, compared with $1.44 billion for the prior-year period.

The stock is currently down $4.49 to $49.40 on 13.8K shares.

Shares of Exelixis, Inc. (EXEL) are higher by 50.38% to $5.88 in pre-market trading on Monday after the company announced positive top-line results from METEOR, the Phase 3 pivotal trial of Cabozantinib vs. Everolimus in patients with metastatic renal cell carcinoma.

Exelixis said the trial met its primary endpoint of demonstrating a statistically significant increase in progression-free survival in the first 375 randomized patients as determined by an independent radiology committee.

Yahoo! Inc. (YHOO) shares gained 0.58% to $39.91 in pre-market trading following the company’s initial filing with the SEC for the planned spin-off of its 16% Alibaba (BABA) stake. The spin-off expected to be completed in Q415.

Horizon Pharma plc (HZNP) shares climbed 6.77% to $39.59 in pre-market trading after saying its sees 2Q15 net sales in the range of $170 to $172 million, which represents an increase of approximately 160% as compared to 2Q14. The company also raised its fully fiscal 2015 revenenu and EBITDA guidance.

Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.